About Gyre Therapeutics
Gyre Therapeutics is a company based in San Diego (United States) founded in 2002.. The company has 5 employees as of December 31, 2024. Gyre Therapeutics has completed 1 acquisition, including Cullgen. Gyre Therapeutics offers products and services including Hydronidone and Pirfenidone Capsules. Gyre Therapeutics operates in a competitive market with competitors including NGM Biopharmaceuticals, Nimbus Therapeutics, Altimmune, Mirum Pharmaceuticals and Madrigal Pharmaceuticals, among others.
- Headquarter San Diego, United States
- Employees 5 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
- Legal Name Gyre Therapeutics, Inc.
-
Annual Revenue
$105.76 M-6.78as on Dec 31, 2024
-
Net Profit
$12.09 M0as on Dec 31, 2024
-
EBITDA
$17.82 M-12.35as on Dec 31, 2024
-
Latest Funding Round
$5 M (USD), Post-IPO
Oct 30, 2023
-
Investors
-
Employee Count
5
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Gyre Therapeutics
Gyre Therapeutics is a publicly listed company on the NASDAQ with ticker symbol GYRE in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Gyre Therapeutics
Gyre Therapeutics offers a comprehensive portfolio of products and services, including Hydronidone and Pirfenidone Capsules. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Therapy for MASH and related liver fibrosis conditions.
Medication for pulmonary complications in oncology.
Funding Insights of Gyre Therapeutics
- Total Funding Total Funding
- Total Rounds 1
- Last Round Post-IPO — $5.0M
-
First Round
First Round
(30 Oct 2023)
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2023 | Amount | Post-IPO - Gyre Therapeutics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by Gyre Therapeutics
Gyre Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Cullgen. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Developer of small molecules targeting the ubiquitin-proteasome system
|
2018 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Gyre Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Gyre Therapeutics Comparisons
Competitors of Gyre Therapeutics
Gyre Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as NGM Biopharmaceuticals, Nimbus Therapeutics, Altimmune, Mirum Pharmaceuticals and Madrigal Pharmaceuticals, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Biologics are developed for cardio-metabolic and liver diseases.
|
|
| domain | founded_year | HQ Location |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
Vaccines for infectious diseases and solid tumors are developed.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics are developed for rare diseases treatment.
|
|
| domain | founded_year | HQ Location |
Develops small molecule drugs for the treatment of cardiovascular and metabolic diseases and non-alcoholic steatohepatitis
|
|
| domain | founded_year | HQ Location |
Protein biologics are developed for treating rare diseases.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Gyre Therapeutics
Frequently Asked Questions about Gyre Therapeutics
When was Gyre Therapeutics founded?
Gyre Therapeutics was founded in 2002 and raised its 1st funding round 21 years after it was founded.
Where is Gyre Therapeutics located?
Gyre Therapeutics is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Who is the current CEO of Gyre Therapeutics?
Han Ying is the current CEO of Gyre Therapeutics.
How many employees does Gyre Therapeutics have?
As of Dec 31, 2024, the latest employee count at Gyre Therapeutics is 5.
What is the annual revenue of Gyre Therapeutics?
Annual revenue of Gyre Therapeutics is $105.76M as on Dec 31, 2024.
What does Gyre Therapeutics do?
Developer of anti-fibrotic therapeutics for a variety of chronic organ diseases. The company is advancing multiple pipeline programs addressing organ fibrosis, including F351 in CHB-associated liver fibrosis.
Who are the top competitors of Gyre Therapeutics?
Gyre Therapeutics's top competitors include Nimbus Therapeutics, NGM Biopharmaceuticals and Madrigal Pharmaceuticals.
What products or services does Gyre Therapeutics offer?
Gyre Therapeutics offers Hydronidone and Pirfenidone Capsules.
Is Gyre Therapeutics publicly traded?
Yes, Gyre Therapeutics is publicly traded on NASDAQ under the ticker symbol GYRE.
How many acquisitions has Gyre Therapeutics made?
Gyre Therapeutics has made 1 acquisition, including Cullgen.
What is Gyre Therapeutics's ticker symbol?
The ticker symbol of Gyre Therapeutics is GYRE on NASDAQ.